31104 recent Wall Street rating changes — with our own star rating shown next to every analyst we independently track.
Track the latest analyst rating changes from Wall Street brokerages: stock upgrades, downgrades and price-target revisions, updated through the day. Unlike a plain ratings feed, every change here is matched — where we can — to the analyst's independent track record on 13Foresight, so you can see at a glance whether the person behind the call has actually been accurate. Analysts we rank show a ★★★★☆ score and link to their full performance page; firms link to their pooled track record. Use the tabs below to filter by change type.
| When | Stock | Change | Analyst | Rating | Price Target |
|---|---|---|---|---|---|
|
Sep 09
18:58 UTC
|
EXE
Expand Energy
|
◎ Target | John Freeman ★★★★☆ #886 | Strong-Buy | $145.00→ $147.00+1.4% |
|
Sep 09
18:58 UTC
|
EPR
EPR Properties
|
◎ Target | Anthony Paolone ★★★☆☆ #1658 | Overweight | $62.00→ $65.00+4.8% |
|
Sep 09
18:58 UTC
|
DEI
Douglas Emmett
|
◎ Target | Anthony Paolone ★★★☆☆ #1658 | Neutral | $15.00→ $16.00+6.7% |
|
Sep 09
18:58 UTC
|
CMC
Commercial Metals
|
◎ Target | Bennett Moore ★★★★☆ #778 | Overweight | $86.00→ $83.00-3.5% |
|
Sep 09
18:58 UTC
|
CLF
Cleveland-Cliffs
|
◎ Target | Bennett Moore ★★★★☆ #778 | Neutral | $11.00→ $13.00+18.2% |
|
Sep 09
18:58 UTC
|
BRZE
Braze
|
◎ Target | Alexei Gogolev ★★★☆☆ #1662 | Overweight | $35.00→ $34.00-2.9% |
|
Sep 09
18:58 UTC
|
BRZE
Braze
|
◎ Target | Taylor McGinnis ★★★★★ #250 | Buy | $28.00→ $32.00+14.3% |
|
Sep 09
18:58 UTC
|
BRZE
Braze
|
◎ Target | Brian Peterson ★★☆☆☆ #2476 | Outperform | $27.00→ $33.00+22.2% |
|
Sep 09
18:58 UTC
|
BRZE
Braze
|
◎ Target | David Hynes ★★★★★ #281 | Buy | $35.00→ $37.00+5.7% |
|
Sep 09
18:58 UTC
|
BBOT
BridgeBio Oncology Therapeutics
|
◎ Target | Sean McCutcheon ★★★☆☆ #1028 | Outperform | $24.00→ $22.00-8.3% |
|
Sep 09
18:58 UTC
|
BBOT
BridgeBio Oncology Therapeutics
|
◎ Target | John Newman ★★★☆☆ #1516 | Buy | $23.00→ $20.00-13.0% |
|
Sep 09
18:58 UTC
|
TLTZY
Tele2
|
↓ Downgrade | firm only | Outperform→ Neutral | |
|
Sep 09
18:58 UTC
|
TEF
Telefonica
|
↑ Upgrade | firm only | Neutral | |
|
Sep 09
17:58 UTC
|
UCB
United Community Banks
|
◎ Target | Stephen Scouten ★★★★☆ #343 | Neutral | $37.00→ $38.00+2.7% |
|
Sep 09
17:58 UTC
|
GEMI
Gemini Space Station
|
◎ Target | James Yaro ★★★★☆ #405 | Sell | $3.50→ $4.00+14.3% |
|
Sep 09
17:58 UTC
|
ETOR
eToro Group
|
◎ Target | James Yaro ★★★★☆ #405 | Neutral | $32.00→ $36.00+12.5% |
|
Sep 09
17:58 UTC
|
DYN
Dyne Therapeutics
|
◎ Target | Michael Ulz ★★★☆☆ #1946 | Overweight | $45.00→ $36.00-20.0% |
|
Sep 09
17:58 UTC
|
COIN
Coinbase Global
|
◎ Target | James Yaro ★★★★☆ #405 | Buy | $196.00→ $219.00+11.7% |
|
Sep 09
17:58 UTC
|
CHYM
Chime Financial
|
◎ Target | Timothy Chiodo ★★★★☆ #324 | Neutral | $28.00→ $31.00+10.7% |
|
Sep 09
17:58 UTC
|
CHYM
Chime Financial
|
◎ Target | James Faucette ★★★☆☆ #1033 | Overweight | $39.00→ $40.00+2.6% |
|
Sep 09
17:58 UTC
|
CHYM
Chime Financial
|
◎ Target | Patrick Moley ★★★★☆ #681 | Overweight | $35.00→ $40.00+14.3% |
|
Sep 09
17:58 UTC
|
ABM
ABM Industries
|
◎ Target | Joshua Chan ★★★☆☆ #1291 | Neutral | $45.00→ $51.50+14.4% |
|
Sep 09
16:58 UTC
|
PHVS
Pharvaris
|
◎ Target | Joseph Schwartz ★★★★☆ #926 | Outperform | $50.00→ $65.00+30.0% |
|
Sep 09
16:58 UTC
|
MRK
Merck & Co., Inc.
|
◎ Target | Daina Graybosch ★★★☆☆ #1338 | Outperform | $127.00→ $161.00+26.8% |
|
Sep 09
16:58 UTC
|
EVMN
Evommune
|
◎ Target | Thomas Smith ★★★☆☆ #1672 | Outperform | $28.00→ $22.00-21.4% |
|
Sep 09
16:58 UTC
|
BXP
BXP
|
◎ Target | Michael Lewis ★★★★☆ #601 | Hold | $64.00→ $68.00+6.2% |
|
Sep 09
15:58 UTC
|
TTAN
ServiceTitan
|
◎ Target | Parker Lane not yet tracked | Buy | $125.00→ $100.00-20.0% |
|
Sep 09
15:58 UTC
|
RVMD
Revolution Medicines
|
◎ Target | Laura Prendergast ★★☆☆☆ #2335 | Buy | $215.00→ $230.00+7.0% |
|
Sep 09
15:58 UTC
|
PYXS
Pyxis Oncology
|
◎ Target | Derek Archila ★★★☆☆ #1939 | Overweight | $12.00→ $19.00+58.3% |
|
Sep 09
15:58 UTC
|
PAYX
Paychex
|
◎ Target | David Grossman ★★★★★ #123 | Hold | $110.00→ $130.00+18.2% |
|
Sep 09
15:58 UTC
|
JILL
J.Jill
|
◎ Target | Janine Stichter ★★★☆☆ #1088 | Buy | $18.00→ $25.00+38.9% |
|
Sep 09
15:58 UTC
|
BBOT
BridgeBio Oncology Therapeutics
|
◎ Target | Laura Prendergast ★★☆☆☆ #2335 | Buy | $23.00→ $15.00-34.8% |
|
Sep 09
15:58 UTC
|
ADBE
Adobe
|
◎ Target | Parker Lane not yet tracked | Hold | $200.00→ $225.00+12.5% |
|
Sep 09
15:58 UTC
|
TMO
Thermo Fisher Scientific
|
↓ Downgrade | firm only | Market Perform | |
|
Sep 09
15:58 UTC
|
TMO
Thermo Fisher Scientific
|
↓ Downgrade | Brandon Couillard ★★★★☆ #891 | Overweight→ Underweight | |
|
Sep 09
15:58 UTC
|
TMO
Thermo Fisher Scientific
|
↓ Downgrade | firm only | Buy→ Underperform | |
|
Sep 09
15:58 UTC
|
TMO
Thermo Fisher Scientific
|
↓ Downgrade | firm only | Buy→ Hold | |
|
Sep 09
14:58 UTC
|
ZWS
Zurn Elkay Water Solutions Cor
|
◎ Target | Bryan Blair ★★★☆☆ #1549 | Outperform | $58.00→ $60.00+3.4% |
|
Sep 09
14:58 UTC
|
VALE
Vale
|
◎ Target | Bob Brackett ★★★★☆ #670 | Market Perform | $12.00→ $12.50+4.2% |
|
Sep 09
14:58 UTC
|
TTAN
ServiceTitan
|
◎ Target | Michael Turrin ★★★★☆ #360 | Overweight | $115.00→ $105.00-8.7% |
|
Sep 09
14:58 UTC
|
TTAN
ServiceTitan
|
◎ Target | Andrew Sherman ★★★★★ #48 | Buy | $125.00→ $100.00-20.0% |
|
Sep 09
14:58 UTC
|
SYK
Stryker
|
◎ Target | Larry Biegelsen ★★★★★ #243 | Overweight | $418.00→ $348.00-16.7% |
|
Sep 09
14:58 UTC
|
ROIV
Roivant Sciences
|
◎ Target | Yaron Werber ★★☆☆☆ #2256 | Buy | $50.00→ $55.00+10.0% |
|
Sep 09
14:58 UTC
|
RIO
Rio Tinto
|
◎ Target | Bob Brackett ★★★★☆ #670 | Outperform | $88.50→ $89.50+1.1% |
|
Sep 09
14:58 UTC
|
RAL
Ralliant
|
◎ Target | Ian Zaffino ★★★☆☆ #1472 | Outperform | $75.00→ $80.00+6.7% |
|
Sep 09
14:58 UTC
|
QCOM
Qualcomm
|
◎ Target | Srini Pajjuri ★★★★★ #149 | Sec→ r Perform | $160.00→ $180.00+12.5% |
|
Sep 09
14:58 UTC
|
PHVS
Pharvaris
|
◎ Target | Yanan Zhu ★★★☆☆ #1243 | Overweight | $55.00→ $65.00+18.2% |
|
Sep 09
14:58 UTC
|
PAYX
Paychex
|
◎ Target | Jason Kupferberg ★★★★☆ #755 | Underweight | $95.00→ $111.00+16.8% |
|
Sep 09
14:58 UTC
|
ORA
Ormat Technologies
|
◎ Target | Noah Kaye ★★★☆☆ #1830 | Outperform | $141.00→ $145.00+2.8% |
|
Sep 09
14:58 UTC
|
NEM
Newmont
|
◎ Target | Bob Brackett ★★★★☆ #670 | Outperform | $147.00→ $144.00-2.0% |
An analyst rating change is when a Wall Street brokerage updates its recommendation on a stock — an upgrade (e.g. Hold → Buy), a downgrade (e.g. Buy → Sell), or a price-target revision (raising or lowering the expected share price). This page lists the most recent changes across U.S. markets.
Where we independently track the analyst, each change shows our own star rating and accuracy rank, computed from real historical price performance — not the brokerage's own marketing. That lets you judge whether the analyst behind a call has actually been right before.
The feed refreshes several times a day, so new upgrades, downgrades and price-target changes appear the same day they are published. Each row shows the date and time we recorded it.
No. A rating change is one analyst's opinion, not investment advice. Track records vary widely — which is exactly why we attach each analyst's independent accuracy. Always do your own research.